No Data
No Data
No Data
No Data
No Data
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients With Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
PR NewswireApr 24 10:20 ET
AnaptysBio Names Thomas Smart as CEO >ANAB
AnaptysBio Names Thomas Smart as CEO >ANAB
Dow JonesApr 24 09:01 ET
Express News | Actym Therapeutics Appoints Thomas Smart as CEO
Moomoo 24/7Apr 24 09:00 ET
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HP
PR NewswireMar 28 16:05 ET
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)
TipRanksMar 26 08:10 ET
Precigen Cut to Underweight From Neutral by JP Morgan
Precigen Cut to Underweight From Neutral by JP Morgan
Dow JonesMar 22 12:22 ET
No Data
No Data